CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
Authors:
- Elisabetta ZanattaElisabetta Zanatta
- Andrea MartiniAMAndrea Martini
- Roberto DepascaleRDRoberto Depascale
- Anna GambaAGAnna Gamba
- Marta TonelloMTMarta Tonello
- Mariele GattoMGMariele Gatto
- Chiara GiraudoCGChiara Giraudo
- Elisabetta BalestroEBElisabetta Balestro
- Andrea DoriaADAndrea Doria
- Luca IaccarinoLILuca Iaccarino
Open Access
- 12 May 2023
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 13 (10) , 1715
Abstract
Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by high-resolution CT. CCL18 and OX40L serum levels were measured by validated ELISA assays in 93 patients and 35 controls. At the 2-year follow-up, PF-ILD was evaluated according to the INBUILD criteria. Results. ILD was diagnosed in 50 (53.7%) patients. CCL18 serum levels were higher in IIMs patients vs. controls (232.9 [IQR 134.7–399.07] vs. 48.4 [29.9–147.5], p < 0.0001), with no difference for OX40L. IIMs-ILD patients exhibited higher levels of CCL18 than those without ILD (306.8 [190.8–520.5] vs. 162 [75.4–255.8], p < 0.0001). High CCL18 serum levels were independently associated with IIMs-ILD diagnosis. At follow-up, 22/50 (44%) patients developed a PF-ILD. Patients who developed PF-ILD had higher CCL18 serum levels than non-progressors (511 [307–958.7] vs. 207.1 [149.3–381.7], p < 0.0001). Multivariate logistic regression analysis revealed CCL18 as the only independent predictor of PF-ILD (OR 1.006 [1.002–1.011], p = 0.005). Conclusions. Although in a relatively small sample, our data suggest that CCL18 is a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD.Keywords
This publication has 27 references indexed in Scilit:
- OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper ResponseImmunity, 2015
- Myositis autoantibodies and clinical phenotypesAutoimmunity Highlights, 2014
- Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosisEuropean Respiratory Journal, 2014
- Identification of human CCR8 as a CCL18 receptorJournal of Experimental Medicine, 2013
- CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseasesRespiratory Medicine, 2013
- Phenotypes of Peripheral Blood Lymphocytes and Cytokine Expression in Polymyositis and Dermatomyositis before Treatment and after Clinical RemissionClinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2012
- Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processesJournal of Leukocyte Biology, 2005
- 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The NetherlandsNeuromuscular Disorders, 2004
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975